The Cold Open
Ipamorelin is pitched as the cleanest way to raise your growth hormone levels. No cortisol spike, no prolactin bump, just a targeted nudge to the pituitary. That part is true. The part that doesn't make it into the clinic pitch is that Ipamorelin was tested in two Phase II human trials and, in both, failed to beat placebo on its primary endpoints. This month: what Ipamorelin actually does, what the human trials actually found, and why the marketing narrative skips the most informative chapter of the story.
Peptide of the Month: Ipamorelin
What it is. Ipamorelin is a five-amino-acid synthetic peptide developed by Novo Nordisk chemists in the late 1990s. It was the first truly selective growth-hormone-releasing peptide, meaning it hits the receptor that triggers GH release without activating the stress-hormone pathway. Earlier peptides in the same class (GHRP-2, GHRP-6) also bumped cortisol, ACTH, and prolactin. Ipamorelin did not. That selectivity is the thing it's famous for and the thing the marketing rightly emphasizes.
What it's supposedly for. Muscle growth, fat loss, better sleep, recovery, anti-aging. Clinics pitch it as a gentler, safer alternative to synthetic GH. Often stacked with CJC-1295 in compounding protocols.
The evidence as of today. The pharmacology is settled. A 1998 preclinical study established Ipamorelin's selective GH profile. A 1999 Phase I trial in healthy men confirmed it in humans: a clean, dose-dependent GH pulse, two-hour half-life, well tolerated. A 2001 rat study showed it preserved bone formation during glucocorticoid exposure. Then two Phase II trials tested it for postoperative ileus (the sluggish gut period after abdominal surgery). Both trials, completed in 2010 and 2014, reported good safety but failed to beat placebo on primary motility endpoints.
One thing to know: "safe" is not "effective." The Ipamorelin file is unusual in that it has robust safety data from real human trials. It also has two modern, placebo-controlled Phase II trials that failed their primary endpoints.
The first selective GH secretagogue. Clean mechanism, decent safety, zero positive Phase II trials for any human indication.
The catch. Not FDA-approved. Every US vial comes from a research-chemical vendor or compounding pharmacy. The clinic pitch leans heavily on the pharmacology (it raises GH, it doesn't raise cortisol) and skips past the Phase II trial outcomes. Raising GH is a mechanism. Raising GH producing a meaningful clinical benefit in healthy adults, for muscle or body composition, has not been demonstrated in any modern controlled trial.
Myth Check: "Ipamorelin is clinically proven"
You will hear this framing everywhere. Ipamorelin has "clinical studies," "human trials," "proven safety and efficacy."
Half true. The human trials exist. They demonstrated Ipamorelin is well tolerated and does what it says on the mechanism label: raises GH without raising stress hormones. What they did not demonstrate is efficacy for any clinical outcome. The only Phase II efficacy trials tested a GI indication, not muscle growth or body composition, and both missed their primary endpoints. No trial has tested the claims the clinics actually make.
The rule: "Clinically studied" means the drug has been in a study. It does not mean the study showed it worked. Always ask what the endpoint was and whether it was hit.
Not medical advice. Most peptides discussed in this newsletter are investigational or research chemicals. Talk to a clinician before starting anything.